Pharmaceutical formulations comprising paraoxonase
View Patent ↗The present invention provides a pharmaceutical formulation comprising paraoxonase (PON), a purification and stabilization method of PON, and an agent for prophylactic and/or therapeutic treatment of a disease resulting from ischemia reperfusion and/or cerebral infarction containing PON as an active ingredient.
1. A method for improving prognosis, neurological symptoms, or motor dysfunction of a disease resulting from cerebral infarction, comprising:
intravenously administering an effective amount of paraoxonase in combination with an effective amount of 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate to improve one of prognosis, neurological symptoms and motor dysfunction of a disease resulting from cerebral infarction to a patient in need thereof,
wherein the paraoxonase is a purified paraoxonase having a specific activity of not less than 500 U/A 280 .
2. The method of claim 1 , wherein the intravenously administering of the effective amount of paraoxonase comprises intravenously administering the effective amount of paraoxonase in the presence of a polyol.
3. The method of claim 1 , wherein the intravenously administering of the effective amount of paraoxonase comprises intravenously administering the effective amount of paraoxonase in the presence of a glycerol.
4. The method of claim 1 , wherein the paraoxonase is a purified paraoxonase having a specific activity in a range of 500 to 2000 U/A 280 .
5. The method of claim 1 , wherein the paraoxonase is a purified paraoxonase having a specific activity in a range of 500 to 1800 U/A 280 .
6. The method of claim 1 , wherein the intravenously administering of the effective amount of paraoxonase comprises intravenously administering an effective amount of a detergent to stabilize an activity of the paraoxonase in combination.
7. The method of claim 1 , wherein the intravenously administering of the effective amount of paraoxonase comprises intravenously administering 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate in an amount of about 0.01 w/v % to about 1 w/v % in combination with paraoxonase.
8. The method of claim 1 , wherein the intravenously administering of the effective amount of paraoxonase comprises intravenously administering 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate in an amount of 0.05 w/v % to 0.5 w/v % in combination with paraoxonase.
9. The method of claim 1 , wherein the intravenously administering of the effective amount of paraoxonase comprises intravenously administering 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate in an amount of 0.05 w/v % in combination with paraoxonase.
10. The method of claim 9 , wherein paraoxonase is administered at a concentration of 10 mg/mL.
11. A method for improving prognosis, neurological symptoms, or motor dysfunction of a disease resulting from cerebral infarction, comprising:
intravenously administering an effective amount of paraoxonase in combination with 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate in an amount of about 0.01 w/v % to 1 w/v % once daily for 1 to 14 days to improve one of prognosis, neurological symptoms and motor dysfunction of a disease resulting from cerebral infarction to a patient in need thereof,
wherein the intravenously administering of the combination is started within 48 hours after onset of a disease resulting from cerebral infarction, and the paraoxonase is a purified paraoxonase having a specific activity of not less than 500 U/A 280 .
12. The method of claim 11 , wherein the combination is administered intravenously once daily for 1 to 7 days.
13. The method of claim 12 , wherein the combination is administered intravenously within 24 hours after onset of a disease resulting from cerebral infarction.
14. The method of claim 12 , wherein the combination is administered intravenously within 12 hours after onset of a disease resulting from cerebral infarction.
15. The method of claim 12 , wherein the combination is administered intravenously within 3 hours after onset of a disease resulting from cerebral infarction.
16. The method of claim 11 , wherein the intravenously administering of the effective amount of paraoxonase comprises intravenously administering 3[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate in an amount of 0.05 w/v % to 0.5 w/v % in combination with paraoxonase.
17. The method of claim 11 , wherein the intravenously administering of the effective amount of paraoxonase comprises intravenously administering 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate in an amount of 0.05 w/v % in combination with paraoxonase.
18. The method of claim 17 , wherein paraoxonase is administered at a concentration of 10 mg/mL.